Q3 2024
Released Nov 12, 2024, after the close
10-Q filed Nov 12, 2024, 43 days after period end · 0001628280-24-047130
Q3 2024 · 10-Q
Revenue$209.00K$209.00K — vs Q3 2023no prior Q2 2024 on file
Net Income-$52.52M-$52.52M N/M vs Q3 2023N/M vs Q2 2024
EPS Diluted-$0.44-$0.44 N/M vs Q3 2023N/M vs Q2 2024
Operating Income-$54,232,000N/M
Operating Cash Flowderived-$25,912,000N/M
Free Cash Flowderived-$27,189,000N/M
Margins · derived
Operating margin-25948.3%
Net margin-25128.2%
What the release said
The release
Same quarter
| Metric | Q3 2024 | Q3 2023 | Q3 2022 | Q3 2021 |
|---|---|---|---|---|
| Revenue | $209.00K | $0.00 | — | — |
| Net Income | -$52.52M | -$50.71M | -$29.35M | -$16.41M |
| EPS Diluted | -$0.44 | -$0.55 | -$1.61 | -$1.52 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Prime Medicine, Inc. · CIK 1894562 · Engraved from SEC EDGAR